Modifying chromatin and concepts of cancer

Current Opinion in Genetics and Development

Volumn 9, Issue 2, 1999, Pages 175-184

  Jacobson, Sandra ^a   Pillus, Lorraine ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR;

CANCER; CHROMATIN STRUCTURE; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION;

EID: 0033118944     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(99)80027-6     Document Type: Article

References (102)

1. Kadonaga JT: Eukaryotic transcription: An interlaced network of transcription factors and chromatin modifying machines. Cell 1998, 92:307-313.
2. Struhl K: Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998, 12:599-606.
3. Kuo M-H, Alis CD: Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998, 20:615-626.
4. Utley RT, Ikeda K, Grant PA, Côté J, Steger DJ, Eberharter A, John S, Workman JL: Transcriptional activators direct histone acetyltransferase complexes to nucleosomes. Nature 1998, 394:498-502. These studies demonstrate that two native yeast HAT complexes, NuA4 and NuA3, can be targeted to nucleosomes by a VP16 transcriptional activation domain to increase transcription in vitro. Significantly, a catalytic subunit of NuA4 is homologous to two proteins with demonstrated HAT activity, human Tip60 and yeast Esa1 p, and one putative HAT, human MOZ (see 'MOZ gene fusions' section and [54,58•,59•]).
5. Grant PA, Duggan L, Côté J, Roberts SM, Brownell JE, Candau R, Ohba R, Owen-Hughes T, Allis CD, Winston F et al.: Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: Characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 1997, 11:1640-1650. This study describes the characterization of two distinct multisubunit HAT complexes isolated from yeast. The ADA and SAGA complexes contain the transcription-related HAT, Gcn5p, in association with adaptor proteins (Adas) and/or components of the basal transcription apparatus (Spts), thereby strengthening the link between histone acetylation and transcription activation.
6. Candau R, Zhou JX, Allis CD, Berger SL: Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. EMBO J 1997, 16:555-565.
7. Grant PA, Schieltz D, Pray-Grant MG, Steger DJ, Reese JC, Yates JR III, Workman JL: A subset of TAF(II)s are integral components of the SAGA complex required for nucleosome acetylation and transcriptional stimulation. Cell 1998, 94:45-53. Further subunit analysis of the yeast Spt-Ada-Gcn5-acetyltransferase (SAGA) complex (see [5•]) reveals the presence of a distinct subset of TATA-binding protein-associated factors (TAFs) thereby emphasizing their roles in transcriptional activation at the level of chromatin modification.
8. Hahn S: The role of TAFs in RNA polymerase II transcription. Cell 1998, 95:579-582.
9. Cairns BR, Lorch Y, Li Y, Zhang MC, Lacomis L, Erdjument-Bromage H, Tempst P, Du J, Laurent B, Kornberg RD: RSC, an essential, abundant chromatin-remodeling complex. Cell 1996, 87:1249-1260.
10. Pollard K, Peterson CL: Role for ADA/GCN5 products in antagonizing chromatin-mediated transcriptional repression. Mol Cell Biol 1997, 17:6212-6222. Mutations in subunits of the transcription-related Gcn5p HAT complexes are shown to have phenotypes similar to mutations in subunits of the SWI/SNF chromatin remodeling complex in yeast. The striking overlap in genes affected by mutations in HAT and SWI/SNF complexes suggest concerted action of these remodeling complexes in transcription regulation of limited genetic loci.
11. Holstege FC, Jennings EG, Wyrick JJ, Lee TI, Hengartner CJ, Green MR, Golub TR, Lander ES, Young RA: Dissecting the regulatory circuitry of a eukaryotic genome. Cell 1998, 95:717-728.
12. Shikama N, Lyon J, LaThangue NB: The p300/CBP family: Integrating signals with transcription factors and chromatin. Trends Cell Biol 1997, 7:230-236.
13. Giles RH, Peters DJM, Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Gener 1998, 14:178-183.
14. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG: A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
15. Shi Y, Seto E, Chang LS, Shenk T: Transcriptional repression by YY1, a human GLI-Kruppel-related protein, and relief of repression by adenovirus E1A protein. Cell 1991, 67:377-388.
16. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y: A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324.
17. Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany A, D'Andrea A, Livingston DM: Cooperation of Stat2 and p300/CBP in signaling induced by interferon-alpha. Nature 1996, 383:344-347.
18. Puri PL, Sartorelli V, Yang XJ, Hamamori Y, Ogryzko VV, Howard BH, Kedes L, Wang JY, Graessmann A, Nakatani Y, Levrero M: Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. Mol Cell 1997, 1:35-45.
19. Blanco JC, Minucci S, Lu J, Yang XJ, Walker KK, Chen H, Evans RM, Nakatani Y, Ozato K: The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev 1998, 12:1638-1651. This study demonstrates that PCAF, a CBP/p300-associated factor with HAT activity, is a nuclear receptor coactivator. Association of PCAF with ligand-bound nuclear receptors is facilitated by dissociation of a co-repressor complex and can be p300/CBP-independent.
20. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90:569-580. This study provided mechanistic insight into how a nuclear hormone coactivator may function to transcriptionally activate target genes by demonstrating intrinsic HAT activity for the coactivator as well as a specific interaction with another HAT, the p300/CBP-associated factor, PCAF.
21. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG: The transcriptional co-activator P/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387:677-684. A novel mammalian factor, P/CIP, with homology to known nuclear receptor coactivators SRC-1/NcoA1 and TIF2/NcoA2/GRIP1 is identified as being required for transcriptional activation of nuclear receptors and other CBP/p300-dependent transcription factors.
22. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna N, Onate SA, Tsai SY, Tsai M-J, O'Malley B: Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 1997, 389:194-198. SRC-1 has HAT activity and interacts with PCAF (see [19•-21•]).
23. McKenna NJ, Nawaz Z, Tsai SY, Tsai MJ, O'Malley BW: Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci USA 1998, 95:11697-11702.
24. Korzus E, Torchia J, Rose DW, Xu L, Kurokawa R, McInerney EM, Mullen TM, Glass CK, Rosenfeld MG: Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279:703-707.
25. Xu L, Lavinsky RM, Dasen JS, Flynn SE, McInerney EM, Mullen TM, Heinzel T, Szeto D, Korzus E, Kurokawa R et al.: Signal-specific co-activator domain requirements for Pit-1 activation. Nature 1998, 395:301-306. This study examines requirements for assembling a homeodomain transcription factor into a corepressor versus a coactivator complex. The coactivator complex shows differential requirements for HAT activities of CBP or PCAF in directing transcriptional activation via different signal transduction pathways.
26. Bannister AJ, Kouzarides T: The CBP co-activator is a histone acetyltransferase. Nature 1996, 384:641-643.
27. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y: The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996, 87:953-959.
28. Martinez-Balbás MA, Bannister AJ, Martin K, Haus-Seuffert P, Meisterernst M, Kouzarides T: The acetyltransferase activity of CBP stimulates transcription. EMBO J 1998, 17:2886-2893.
29. Nakajima T, Uchida C, Anderson SF, Parvin JD, Montminy M: Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors. Genes Dev 1997, 11:738-747.
30. Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D: Acetylation of HMG I(Y) by CBP turns off IFN β expression by disrupting the enhanceosome. Mol Cell 1998, 2:457-467.
31. Gu W, Roeder RG: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606. This study and [32•] describe a role for post-translational modifications in altering p53 sequence-specific DNA binding and activation activities and underscore the significance of p300-mediated acetylation of non-histone proteins.
32. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Apella E: DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998, 12:2831-2841. See also [31•]. This study extends the connection between phosphorylation and acetylation of p53 in modulating its transcriptional activity in response to DNA damage. Interestingly, p53 can be acetylated by p300 or PCAF in vitro at different carboxy-terminal sites which is affected by the amino-terminal phosphorylation status of p53.
33. Boyes J, Byfield P, Nakatani Y, Ogryzko V: Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998, 396:594-598.
34. Zhang W, Bieker JJ: Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc Natl Acad Sci USA 1998 95:9855-9860.
35. ∥250 are shown to acetylate components of the PolII core complex, TF∥Eβ and TF∥F. This study thus identifies additional non-histone substrates for these HATs and reinforces the link between acetylation and transcription.
36. Cho H, Orphanides G, Sun X, Yang XJ, Ogryzko V, Lees E, Nakatani Y, Reinberg D: A human RNA polymerase II complex containing factors that modify chromatin structure. Mol Cell Biol 1998, 18:5355-5363. A human PolII complex containing Srb mediator proteins but lacking general transcription factors is found to co-fractionate with a SWI/SNF complex and the histone acetyltransferases CBP and PCAF, thereby providing physical and functional links between chromatin remodeling and transcription.
37. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, Iwama T, Miyaki M: P300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996, 12:1565-1569.
38. Tanaka Y, Naruse I, Maekawa T, Masuya H, Shiroishi T, Ishii S: Abnormal skeletal patterning in embryos lacking a single Cbp allele: A partial similarity with Rubinstein-Taybi syndrome. Proc Natl Acad Sci USA 1997, 94:10215-10220. Heterozygous transgenic mice bearing one inactivated allele of CBP display skeletal patterning abnormalities reminiscent of those seen in humans lacking one functional allele of Cbp and exhibiting Rubenstein-Taybi syndrome, suggesting conservation of CBP function between species.
39. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, Bronson RT, Li E, Livingston DM, Eckner R: Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998, 93:361-372. Transgenic mice in which both alleles of CBP or p300 are inactivated die during embryogenesis. Heterozygous mice with one inactivated allele of p300 display reduced viability during gestation but survivors suffer no gross phenotypic defects. Interestingly, mice heterozygous for both CBP and p300 also die during embryogenesis, suggesting that CBP and p300 share limited overlapping essential functions during development and that their combined gene dosage is important during development.
40. 1 arrest or apoptosis in response to DNA damage. These observations are important in two respects. They implicate CBP/p300 directly in p53 signaling to suggest one way in which CBP/p300 may exert an antiproliferative effect. They also provide a mechanism for how p53, a protein commonly mutated in cancer cells, carries out its protective surveillance function in cells.
41. Gu W, Shi XL, Roeder RG: Synergistic activation of transcription by CBP and p53. Nature 1997, 387:819-823. See annotation [40•].
42. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM: Binding and modulation of p53 by p300/CBP coactivators. Nature 1997, 387:823-827. See annotation [40•].
43. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ: Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 1997, 275:523-527. Inhibition of cyclin E/Cdk2 activity stimulates transcriptional activation by NF-κB, a transcription factor shown to bind the amino terminus of p300 and the activation of which correlates with cell damage and growth arrest. The cyclin E/Cdk2 complex is known to interact with the carboxyl terminus of p300, thereby providing a mechanism for coordinating cell-cycle progression and transcriptional activation through p300.
44. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R: A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995, 374:81-84.
45. Lundblad JR, Kwok RP, Laurance ME, Harter ML, Goodman RH: Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. Nature 1995, 374:85-88.
46. Eckner R, Ludlow JW, Lill NL, Oldread E, Arany Z, Modjtahedi N, DeCaprio JA, Livingston DM, Morgan JA: Association of p300 and CBP with simian virus 40 large T antigen. Mol Cell Biol 1996, 16:3454-3464.
47. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm, FG, Chaganti RS, Civin CJ, Disteche C, Dube I, Frischauf AM ef al.: The translocation t(8;16)(p11 ;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Gene 1996, 14:33-41.
48. Reifsnyder C, Lowell J, Clarke A, Pillus L: Yeast SAS silencing genes and human genes associated with AML and HIV-Tat interactions are homologous with acetyltransferases. Nat Genet 1996, 14:42-49.
49. Ehrenhofer-Murray AE, Rivier DH, Rine J: The role of Sas2, an acetyltransferase homologue of Saccharomyces cerevisiae, in silencing and ORC function. Genetics 1997, 145:923-934.
50. Neuwald AF, Landsman D: GCN5-related histone N-acetyltransferases belong to a diverse superfamily that includes the yeast SPT10 protein. Trends Biochem Sci 1997, 22:154-155.
51. Dutnall RN, Tafrov ST, Sternglanz R, Ramakrishnan V: Structure of the histone acetyltransferase Hat1: A paradigm for the GCN5-related N-acetyltransferase superfamily. Cell 1998, 94: 427-438. This crystal structure of the yeast Hat1 p-AcetylCoA complex provides a foundation for mechanistic understanding of catalytic properties as well as histone substrate specificities of Gcn5-related N-acetyltransferases (GNATs). Importantly, this study also serves as an interpretive guide for HAT mutant phenotypes.
52. Wolf E, Vassilev A, Makino Y, Sali A, Nakatani Y, Burley S: Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase. Cell 1998, 94:439-449. See annotation [51•]. This study presents the structure of another member of the GNAT superfamily but, in this case, of a eubacterial aminoglycoside N-acetyltransferase, which catalyzes acetylation of aminoglycoside antibiotics.
53. Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G: Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 1996, 216:357-366.
54. Yamamoto T, Horikoshi M: Novel substrate specificity of the histone acetyltransferase activity of HIV-1 Tat interactive protein Tip60. J Biol Chem 1997, 272:30595-30598.
55. Hilfiker A, Hilfiker-Kleiner D, Pannuti A, Lucchesi JC: Mof, a putative acetyltransferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J 1997, 16:2054-2060. The Drosophila Mof gene - encoding a putative acetyltransferase of the MYST family, including human MOZ and the yeast SAS genes - is shown to play a role in dosage compensation in Drosophila. Specifically, loss of mof function correlates with loss of an acetylated histone isoform normally associated with increased transcriptional activity of the male X chromosome.
56. Brownell JE, Allis CD: Special HATs for special occasions: Linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 1996, 6:176-184.
57. Turner BM: Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci 1998, 54:21-31.
58. Smith ER, Eisen A, Gu W, Sattah M, Pannuti A, Zhou J, Cook RG, Lucchesi JC, Allis CD: ESA1 is a histone acetyltransferase that is essential for growth in yeast. Proc Natl Acad Sci USA 1998, 95:3561-3565. See also [59•]. The yeast Esa1p is shown to have in vitro HAT activity with unique substrate specificity, distinguishing it as the first yeast SAS gene to encode a protein with HAT activity as well as the only known essential HAT in yeast.
59. Clarke AS, Lowell JE, Jacobson SJ, Pillus L: Esa1p is an essential histone acetyltransferase required for cell cycle progression. Mol Cell Biol 1999, 19:2515-2526. See also [58•]. Characterization of conditional alleles of esa1 reveals a role for this HAT in cell-cycle progression that may be monitored by check-point functions.
60. Carapeti M, Aguiar RC, Goldman JM, Cross NC: A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 1998, 91:3127-3133. This study and [61•] document chromosomal rearrangements in cases of acute leukemias fusing a putative human acetyltransferase, MOZ (see [47]), to a nuclear receptor coactivator, TIF2. As TIF2 can coactivate in a CBP/p300-dependent manner, CBP/p300 is predicted to play a role in this disease.
61. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL: Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood1998, 92:2118-2122. See annotation [60•].
62. Voegel JJ, Heine MJS, Zechel C, Chambon P, Gronemeyer H: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996, 15:3667-3675.
63. Voegel JJ, Heine MJS, Tini M, Vivat V, Chambon P, Gronemeyer H: The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 1998, 17:507-519.
64. Waring PM, Cleary ML: Disruption of a homolog of trithorax by 11q23 translocations: Leukemogenic and transcriptional implications. Curr Top Microbiol Immunol 1997, 220:1-23.
65. Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ: MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc Natl Acad Sci USA 1998, 95:10632-10636.
66. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ: Altered hox expression and segmental identity in M∥-mutant mice. Nature 1995, 378:505-508.
67. Rowley JD, Reshmi S, Sobulo O, Musvee T, Anastasi J, Raimondi S, Schneider N, Barredo JC, Cantu ES, Schlegelberger B et al.: All patients with the t(11;16)(q23;p13.3) that involves MLL and CBP have treatment-related hematologic disorders. Blood 1997, 90:535-541. Studies [67•-70•] document chromosomal rearrangements in hematological malignancies fusing a chromatin component, MLL, to the transcriptional coactivator CBR. Like the MOZ fusions described in [47,60•,61•], CBP is predicted to play a role in disease, possibly though directing aberrant acetylation patterns in affected cell lineages.
68. Taki T, Sako M, Tsuchida M, Hayashi Y: The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997, 89:3945-3950. See annotation [67•].
69. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ: MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci USA 1997, 94:8732-8737. See annotation [67•].
70. Satake N, Ishida Y, Otoh Y, Hinohara S, Kobayashi H, Sakashita A, Maseki N, Kaneko Y: Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation. Genes Chromosom Cancer 1997, 20:60-63. See annotation [67•].
71. Ida K, Kitabayashi I, Taki T, Taniwaki M, Noro K, Yamamoto M, Ohki M, Hayashi Y: Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 1997, 90:4699-4704.
72. Aravind L, Landsman D: AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res 1 998, 26:4413-4421.
73. Ma Q, Alder H, Nelson KK, Chatterjee D, Gu Y, Nakamura T, Canaani E, Croce CM, Siracusa LD, Buchberg AM: Analysis of the murine all-1 gene reveals conserved domains with human ALL-1 and identifies a motif shared with DNA methyltransferases. Proc Natl Acad Sci USA 1993, 90:6350-6354.
74. Zeleznik-Le NJ, Harden AM, Rowley JD: 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci USA 1994, 91:10610-10614.
75. Nan X, Ng H-H, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389. See also [76•]. MeCP2, a protein known to bind methylated CpG sequences, is shown to recruit a histone deactylase complex to repress transcription, thereby linking genomic methylation patterns to acetylation states through a DNA-binding protein.
76. Jones PL, Veenstra GJC, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP: Methylated DNA and MeCp2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19:187-191. See annotation [75•].
77. Stassen MJ, Bailey D, Nelson S, Chinwalla V, Harte PJ. The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Mech Dev 1995, 52:209-223.
78. Nislow C, Ray E, PiLLus L: SET1, a yeast member of the trithorax family, functions in transcriptional silencing and diverse cellular processes. Mol Biol Cell 1997, 8:2421-2436.
79. Rozenblatt-Rosen O, Rozovskaia T, Burakov D, Sedkov Y, Tillib S, Blechman J, Nakamura T, Croce CM, Mazo A, Canaani E: The C-terminal SET domains of ALL-1 and trithorax interact with the INI1 and SNR1 proteins, components of the SWI/SNF complex. Proc Natl Acad Sci USA 1998, 95:4152-4157. The carboxy-terminal SET domain of MLL/ALL-1/HRX is shown to interact with hSNF5 by two-hybrid analysis, in vitro binding studies and co-immunoprecipitation from cultured cells or transgenic flies. This interaction suggests a mechanism for targeting SWI/SNF complexes to chromatin through a discrete functional domain of a non-histone chromatin component.
80. Pollard KJ, Peterson CL: Chromatin remodeling: A marriage between two families? Bioessays 1998, 20:771-780.
81. Perez-Martin J, Johnson AD: The C-terminal domain of Sin1 interacts with the SWI/SNF complex in yeast. Mol Cell Biol 1998, 18:4157-4164. The carboxyl terminus of the yeast Sin1p, an HMG-like protein, is shown to physically interact with the SWI/SNF complex and to interact genetically with histones H3 and H4, suggesting a bridge between SWI/SNF and the nucleosome.
82. Rubnitz JE, Morrissey J, Savage PA, Cleary ML: ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcription activation potential in lymphoid and myeloid cells. Blood 1994, 84:1747-1752.
83. Prasad R, Yano T, Sorio C, Nakamura T, Rallapalli R, Gu Y, Leshkowitz D, Croce CM, Canaani E: Domains with transcriptional regulatory activity within the ALL-1 and AF4 proteins involved in acute leukemias. Proc Natl Acad Sci USA 1995, 92:12160-12164.
84. Corral J, Lavenir I, Impey H, Warren AJ, Forster A, Larson TA, Bell S, McKenzie ANJ, King G, Rabbitts TH: An MLL-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes. Cell 1996, 85:853-861.
85. Welch MD, Drubin DG: A nuclear protein with sequence similarity to proteins implicated in human leukemias is important for cellular morphogenesis and actin cytoskeletal function in Saccharomyces cerevisiae. Mol Biol Cell 1994, 5:617-632.
86. Cairns BR, Henry NL, Kornberg RD: TFG/TAF30/ANC1, a component of the yeast SWI/SNF complex that is similar to the leukemogenic proteins ENL and AF-9. Mol Cell Biol 1996, 16:3308-3316.
87. Hartzog GA, Winston F: Nucleosomes and transcription: Recent lessons from genetics. Curr Opin Genet Dev 1997, 7:192-198.
88. Workman JL, Kingston RE: Alteration of nucleosome structure as a mechanism of transcriptional regulation. Ann Rev Biochem 1998, 67:545-579.
89. Tong JK, Hassig CA, Schnitzler GR, Kingston RE, Schreiber S: Chromatin deacetylation by an ATP-dependent nucleosome remodeling complex. Nature 1998, 395:917-921. This study and [90•] describe novel mammalian complexes immunoprecipitated from human HeLa cells that contain both deacetylase and chromatin-remodelling components, suggesting concerted action of chromatin modifying complexes.
90. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D: The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998, 95:279-289. See annotation [89•].
91. Armstrong JA, Bieker JJ, Emerson BM: A SWI/SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro. Cell 1998, 95:93-104.
92. Wang W, Côté J, Xue Y, Zhou S, Khavari PA, Biggar SR, Muchardt C, Kalpana GV, Goff SP, Yaniv M et al.: Purification and biochemical heterogeneity of the mammalian SWI/SNF complex. EMBO J 1996, 15:5370-5382.
93. Muchardt C, Sardet C, Bourachot B, Onufryk C, Yaniv M: A human protein with homology to Saccharomyces cerevisiae SNF5 interacts with the potential helicase hbrm. Nucleic Acids Res 1995 23:1127-1132.
94. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambras P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394:203-206. This study indicates a role for SWI/SNF in cancer in that somatic biallelic alterations of a human remodeling complex component were found in cells derived from malignant pediatric rhabdoid tumors. The alterations involve carboxy-terminal truncations of hSNF5/INI1, a region known to interact with hSNF2, an ATP-dependent catalytic subunit of the SWI/SNF complex.
95. Ichinose H, Garnier JM, Chambon P, Losson R: Ligand-dependent interaction between the estrogen receptor and the human homologues of SWI2/SNF2. Gene 1997, 188:95-100.
96. Trouche D, LeChalony C, Muchardt C, Yaniv M, Kouzarides T: Rb and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA 1997, 94:11268-11273. Rb, a human tumor suppressor protein is found to complex with E2F1, an S-phase promoting factor and hBRM, a human SWI/SNF component. Rb and hBRM cooperate to repress E2F1 activity, thereby providing one mechanism for the anti-proliferative effect of Rb.
97. Fryer CJ, Archer TK: Chromatin remodelling by the glucocorticoid receptor requires the BRG1 complex. Nature 1998, 393:88-91.
98. Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391:597-601. This study and [99•] show that human Rb can recruit HDAC1 to E2F1 to repress the E2F1-regulated promoter of cyclin E, a cell-cycle regulator. Therefore, the antiproliferative effect of Rb may be mediated in part at the transcriptional level by modifying the acetylation of histones or other chromatin-associated proteins.
99. Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP, Troalen F, Trouche D, Harel-Bellan A: Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 1998, 391:601-605. See annotation [98•].
100. Trouche D, Cook A, Kouzarides T: The CBP co-activator stimulates E2F1/DP1 activity. Nucleic Acids Res 1996, 24:4139-4145.
101. Blobel GA, Nakajima T, Eckner R, Montminy M, Orkin SH: CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. Proc Natl Acad Sci USA 1998, 95:2061-2066.
102. Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM, Darnell JE Jr: Two contact regions between Stat1 and CBP/p300 in interferon γ signaling. Proc Natl Acad Sci USA 1996, 93:15092-15096.